Disease-defining antibodies, such as those against cardiolipin or β2-GPI (including those against domain I), showed a strong association with anamnestic risk of thrombosis; however, they did not predict the future occurrence of TE in this LA-positive patient population. This evidence concerns the gene APOH and Venous thrombosis.